ABSTRACT
BACKGROUND: The angiotensin II (AngII) receptor subtype 2 (AT2 R) is expressed in sensory neurons and may play a role in nociception and neuronal regeneration. METHODS: We used immunostaining with characterized antibodies to study the localization of AT2 R in cultured human and rat dorsal root ganglion (DRG) neurons and a range of human tissues. The effects of AngII and AT2 R antagonist EMA401 on capsaicin responses in cultured human and rat (DRG) neurons were measured with calcium imaging, on neurite length and density with Gap43 immunostaining, and on cyclic adenosine monophosphate (cAMP) expression using immunofluorescence. RESULTS: AT2 R expression was localized in small-/medium-sized cultured neurons of human and rat DRG. Treatment with the AT2 R antagonist EMA401 resulted in dose-related functional inhibition of capsaicin responses (IC50 = 10 nmol/L), which was reversed by 8-bromo-cAMP, and reduced neurite length and density; AngII treatment significantly enhanced capsaicin responses, cAMP levels and neurite outgrowth. The AT1 R antagonist losartan had no effect on capsaicin responses. AT2 R was localized in sensory neurons of human DRG, and nerve fibres in peripheral nerves, skin, urinary bladder and bowel. A majority sub-population (60%) of small-/medium-diameter neuronal cells were immunopositive in both control post-mortem and avulsion-injured human DRG; some very small neurons appeared to be intensely immunoreactive, with TRPV1 co-localization. While AT2 R levels were reduced in human limb peripheral nerve segments proximal to injury, they were preserved in painful neuromas. CONCLUSIONS: AT2 R antagonists could be particularly useful in the treatment of chronic pain and hypersensitivity associated with abnormal nerve sprouting.
Subject(s)
Angiotensin II Type 2 Receptor Blockers/pharmacology , Benzhydryl Compounds/pharmacology , Capsaicin/pharmacology , Isoquinolines/pharmacology , Neurites/drug effects , Receptor, Angiotensin, Type 2/metabolism , Sensory Receptor Cells/drug effects , TRPV Cation Channels/metabolism , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Animals , Cells, Cultured , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Humans , Neurites/metabolism , Rats , Sensory Receptor Cells/metabolism , TRPV Cation Channels/drug effectsABSTRACT
The cannabinoid receptor CB1 is involved in modulation of neuronal hypersensitivity and pain. The aim of this study was to evaluate CB1 receptor levels for the first time in dental pain. A total of 19 patients due for molar extraction were divided into two groups, those with existing dental pain (n=9), and those with no history of pain (n=10). Immunohistochemistry and computer image analysis was used to evaluate CB1-positive nerve fibres in tooth pulp, with neurofilament-immunostaining as a structural nerve marker. CB1-immunoreactive nerve fibres were scattered throughout the tooth pulp and often seen in nerve bundles, but the fibres did not penetrate the subodontoblastic layer. There was no statistically significant change in the CB1 nerve fibre percentage area in the painful group compared to the non-painful group (p=0.146); the neurofilament fibres were significantly reduced in the painful group compared to the controls (p=0.028), but there was no difference in the ratio of CB1 to neurofilaments between the two groups. Thus, CB1 expression is maintained by nerve fibres in painful human dental pulp, and peripherally-restricted CB1 agonists currently in development may advance the treatment of dental pain.
Subject(s)
Dental Pulp/innervation , Receptor, Cannabinoid, CB1/metabolism , Sensory Receptor Cells/metabolism , Toothache/etiology , Toothache/metabolism , Actin Cytoskeleton/chemistry , Actin Cytoskeleton/metabolism , Actin Cytoskeleton/pathology , Adult , Dental Pulp/pathology , Female , Humans , Immunohistochemistry , Male , Middle Aged , Neurofilament Proteins/biosynthesis , Neurofilament Proteins/chemistry , Neurofilament Proteins/metabolism , Nociceptors/chemistry , Nociceptors/metabolism , Nociceptors/pathology , Receptor, Cannabinoid, CB1/biosynthesis , Sensory Receptor Cells/pathology , Toothache/pathology , Young AdultABSTRACT
OBJECTIVE: The capsaicin receptor TRPV1 (transient receptor potential vanilloid type-1) may play an important role in visceral pain and hypersensitivity states. In irritable bowel syndrome (IBS), abdominal pain is a common and distressing symptom where the pathophysiology is still not clearly defined. TRPV1-immunoreactive nerve fibres were investigated in colonic biopsies from patients with IBS, and this was related to abdominal pain. METHODS: Rectosigmoid biopsies were collected from 23 IBS patients fulfilling Rome II criteria, and from 22 controls. Abdominal pain scores were recorded using a validated questionnaire. TRPV1-, substance P- and neuronal marker protein gene product (PGP) 9.5-expressing nerve fibres, mast cells (c-kit) and lymphocytes (CD3 and CD4) were quantified, following immunohistochemistry with specific antibodies. The biopsy findings were related to the abdominal pain scores. RESULTS: A significant 3.5-fold increase in median numbers of TRPV1-immunoreactive fibres was found in biopsies from IBS patients compared with controls (p<0.0001). Substance P-immunoreactive fibres (p = 0.01), total nerve fibres (PGP9.5) (p = 0.002), mast cells (c-kit) (p = 0.02) and lymphocytes (CD3) (p = 0.03) were also significantly increased in the IBS group. In multivariate regression analysis, only TRPV1-immuno-reactive fibres (p = 0.005) and mast cells (p = 0.008) were significantly related to the abdominal pain score. CONCLUSIONS: Increased TRPV1 nerve fibres are observed in IBS, together with a low-grade inflammatory response. The increased TRPV1 nerve fibres may contribute to visceral hypersensitivity and pain in IBS, and provide a novel therapeutic target.
Subject(s)
Abdominal Pain/metabolism , Irritable Bowel Syndrome/metabolism , Nerve Fibers/metabolism , Neurons, Afferent/metabolism , TRPV Cation Channels/metabolism , Abdominal Pain/psychology , Adult , Aged , Anxiety/metabolism , Depression/metabolism , Female , Humans , Immunoenzyme Techniques , Inflammation Mediators/metabolism , Intestinal Mucosa/metabolism , Irritable Bowel Syndrome/psychology , Male , Middle Aged , Pain Measurement/methodsABSTRACT
Burning mouth syndrome (BMS) is often an idiopathic chronic and intractable pain condition, affecting 1.5-5.5% of middle-aged and elderly women. We have studied the heat and capsaicin receptor TRPV1, and its regulator nerve growth factor (NGF), in BMS. Patients with BMS (n=10) and controls (n=10) were assessed for baseline and post-topical capsaicin pain scores, and their tongue biopsies immunostained for TRPV1, NGF, and structural nerve markers neurofilament and peripherin. Nerve fibres penetrating the epithelium were less abundant in BMS (p<0.0001), indicating a small fibre neuropathy. TRPV1-positive fibres were overall significantly increased in BMS (p=0.0011), as were NGF fibres (p<0.0001) and basal epithelial cell NGF staining (p<0.0147). There was a significant correlation between the baseline pain score and TRPV1 (p=0.0143) and NGF fibres (p=0.0252). A significant correlation was observed between baseline and post-capsaicin pain (p=0.0006). Selective TRPV1 and NGF blockers may provide a new therapy for BMS.
Subject(s)
Burning Mouth Syndrome , Gene Expression Regulation/physiology , Nerve Fibers/metabolism , Pain Measurement , TRPV Cation Channels/metabolism , Trigeminal Nerve Diseases/complications , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Burning Mouth Syndrome/etiology , Burning Mouth Syndrome/metabolism , Burning Mouth Syndrome/pathology , Female , Humans , Male , Middle Aged , NAV1.8 Voltage-Gated Sodium Channel , Nerve Growth Factor/metabolism , Neurofilament Proteins/metabolism , Pain Measurement/methods , Sodium Channels/metabolism , Tongue/pathology , Trigeminal Nerve Diseases/pathologyABSTRACT
PURPOSE: Botulinum neurotoxin type A (BoNT/A) is effective in the treatment of intractable detrusor overactivity (DO). In addition to its known inhibitory effect on presynaptic release of acetylcholine by motor terminals, there is increasing evidence that BoNT/A may affect sensory fibers. We investigated a possible effect of BoNT/A on human bladder afferent mechanisms by studying the sensory receptors P2X3 and TRPV1 in biopsies from patients with neurogenic or idiopathic DO. MATERIALS AND METHODS: A total of 38 patients (22 with neurogenic DO, 16 with idiopathic DO) with intractable DO were treated with intradetrusor BoNT/A, and bladder biopsies were taken at 4 and 16 weeks. Urodynamics and voiding diary were also recorded. Specimens were studied immunohistochemically for P2X3, TRPV1 and the pan-neuronal marker PGP9.5, in comparison with controls. RESULTS: P2X3-immunoreactive and TRPV1-immunoreactive (-IR) fibers were decreased at 4 weeks after BoNT/A, and more significantly at 16 weeks (paired t test p=0.0004 and p=0.0008, respectively), when significant improvements were observed in clinical and urodynamic parameters. P2X3-IR fiber decrease was significantly correlated with reduction of urgency episodes at 4 and 16 weeks (p=0.0013 at 4 weeks and p=0.02 at 16 weeks), but not maximum cystometric capacity or detrusor pressures. TRPV1-IR fiber decrease showed a similar trend. PGP9.5-IR suburothelial fibers remained unchanged after treatment at both followups (p=0.85 and p=0.21 at 4 and 16 weeks, respectively). Urothelial cell P2X3-IR and TRPV1-IR also appeared unchanged. CONCLUSIONS: Decreased levels of sensory receptors P2X3 and/or TRPV1 may contribute to the clinical effect of BoNT/A in detrusor overactivity.
Subject(s)
Botulinum Toxins, Type A/administration & dosage , Ion Channels/drug effects , Muscle Hypertonia/drug therapy , Nerve Fibers/drug effects , Neuromuscular Agents/administration & dosage , Receptors, Purinergic P2/drug effects , Sensory Receptor Cells/drug effects , Synaptic Transmission/drug effects , Urinary Bladder, Neurogenic/drug therapy , Urinary Bladder/innervation , Urinary Incontinence/drug therapy , Adult , Afferent Pathways/drug effects , Aged , Biopsy , Botulinum Toxins, Type A/adverse effects , Cystoscopy , Dose-Response Relationship, Drug , Female , Humans , Immunoenzyme Techniques , Injections, Intramuscular , Male , Middle Aged , Muscle Hypertonia/pathology , Nerve Fibers/pathology , Nerve Fibers, Unmyelinated/drug effects , Nerve Fibers, Unmyelinated/pathology , Neuromuscular Agents/adverse effects , Receptors, Purinergic P2X3 , Sensitivity and Specificity , TRPV Cation Channels , Treatment Outcome , Urinary Bladder/pathology , Urinary Bladder, Neurogenic/pathology , Urinary Incontinence/pathology , Urodynamics/drug effects , Urothelium/innervation , Urothelium/pathologyABSTRACT
BACKGROUND: The tetrodotoxin-resistant voltage-gated sodium channel Nav1.8 (SNS1/PN3) is expressed by nociceptors and may play a role in pain states. METHODS: Using specific antibodies for immunohistochemistry, we studied Nav1.8 immunoreactivity in human dental pulp in relation to the neuronal marker neurofilament. Human tooth pulp was extracted from teeth harvested from a total of twenty-two patients (fourteen without dental pain, eight patients with dental pain). RESULTS: Fibres immunoreactive for Nav1.8, were significantly increased on image analysis in the painful group: median (range) Nav1.8 to Neurofilament % area ratio, non-painful 0.059 (0.006-0.24), painful 0.265 (0.13-0.5), P = 0.0019. CONCLUSION: Nav1.8 sodium channels may thus represent a therapeutic target in trigeminal nerve pain states.
ABSTRACT
OBJECTIVE: To compare PGP9.5 and transient receptor potential vanilloid receptor (TRPV1) suburothelial immunoreactivity between controls and patients with spinal neurogenic detrusor overactivity (NDO) before and after treatment with intravesical resiniferatoxin, as suburothelial PGP9.5-staining nerve fibres decrease in patients with spinal NDO who respond to intravesical capsaicin, and TRPV1 is present on these suburothelial nerve fibres in normal and overactive human urinary bladder. PATIENTS AND METHODS: Patients with refractory NDO were enrolled in a prospective, randomized, parallel-group, double-blind, placebo-controlled trial using escalating doses of resiniferatoxin to a maximum of 1 micro mol/L. Flexible cystoscopic bladder biopsies obtained at baseline, 4 weeks after each instillation and at the time of maximum clinical response were compared with biopsies taken from control subjects. Frozen sections were incubated with rabbit antibodies to TRPV1 and PGP9.5, and assessed using standard immunohistochemical methods. PGP9.5 nerve density was analysed using a nerve-counting graticule by an observer unaware of sample origin. Another two independent observers unaware of each other's results used a random grading scale to evaluate TRPV1 nerve fibre density and intensity. The immunohistochemistry results were compared with histology findings (haematoxylin-eosin), and the Mann-Whitney test used to assess any differences (P < 0.05 significant) and the Pearson test for correlation. RESULTS: There were eight controls and 20 patients with spinal NDO, 14 (five clinical responders and nine not) who received the maximum dose of resiniferatoxin. There were more PGP9.5 and TRPV1 nerve fibres in patients with NDO than in controls (P = 0.007 and 0.002, respectively). Immunoreactivity before resiniferatoxin was similar in both groups for both PGP9.5 and TRPV1. In responders there were fewer PGP9.5 and TRPV1-positive fibres after treatment (P = 0.008 for each) but no change in those not responding. Changes after treatment for TRPV1 correlated well with those for PGP9.5 (r = 0.88, P < 0.001). CONCLUSIONS: The decrease of PGP9.5 and TRPV1 immunoreactive nerve fibres in responders to resiniferatoxin (to levels in control tissues) suggests that the increased numbers of nerve fibres in patients with NDO are mainly of sensory origin and express TRPV1. As baseline nerve fibre values were similar in responders and nonresponders, an additional factor may account for the difference in treatment outcome.
Subject(s)
Ion Channels , Receptors, Drug/metabolism , Ubiquitin Thiolesterase/metabolism , Urinary Bladder, Neurogenic/metabolism , Urinary Bladder/metabolism , Urinary Incontinence/metabolism , Administration, Intravesical , Biomarkers , Biopsy/methods , Diterpenes/therapeutic use , Double-Blind Method , Humans , Immunohistochemistry , Middle Aged , Neurotoxins/therapeutic use , Prospective Studies , TRPV Cation Channels , Urinary Bladder/pathology , Urinary Bladder, Neurogenic/drug therapy , Urinary Incontinence/drug therapyABSTRACT
OBJECTIVE: To investigate endothelial nitric oxide synthase (eNOS) immunoreactivity in bladder biopsies from patients with neurogenic detrusor overactivity (NDO) before and after treatment with intravesical resiniferatoxin, and compare this with control material; the distribution of two other vascular markers, von Willebrand Factor (vWF) and the vascular endothelial growth factor (VEGF), was also studied. PATIENTS AND METHODS: Flexible cystoscopic bladder biopsies from eight controls investigated for asymptomatic microhaematuria and 19 patients with refractory spinal NDO enrolled in a clinical trial of intravesical treatment with escalating doses of resiniferatoxin were immunostained with polyclonal rabbit antibodies for eNOS, vWF and VEGF. Fewer baseline NDO specimens (eight) were available for vWF and VEGF staining. Computerized image analysis was used to quantify immunoreactivity, and the Mann-Whitney test for statistical analysis. RESULTS: eNOS immunoreactivity was found in the suburothelium and less often in the urothelium, with a distribution indicating a location in small blood vessels at the urothelium-suburothelium junction. Immunostaining for vWF showed a similar location. There was a trend to higher eNOS values before treatment in those responding than in those not responding to resiniferatoxin (P = 0.059), and a significant reduction in eNOS immunoreactivity after successful treatment (P = 0.016). VEGF staining was weaker but there was a significant increase in pretreatment biopsies of responders to resiniferatoxin (P = 0.048). Clinical and histopathology features were similar in both groups. CONCLUSIONS: The trend for higher eNOS expression in patients with NDO who responded to resiniferatoxin suggests that increased vasculature or vasodilatation in the suburothelium may be necessary for successful intravesical treatment. Further studies with more patients are required to confirm this relationship and to examine the mechanisms underlying changes in vasculature with levels of bladder overactivity.
Subject(s)
Diterpenes/administration & dosage , Neurotoxins/administration & dosage , Nitric Oxide Synthase/metabolism , Urinary Bladder, Neurogenic/drug therapy , Urinary Bladder/enzymology , Administration, Intravesical , Biopsy/methods , Double-Blind Method , Humans , Immunohistochemistry , Middle Aged , Nitric Oxide Synthase Type III , Prospective Studies , Urinary Bladder/pathology , Urinary Bladder, Neurogenic/enzymology , Urinary Bladder, Neurogenic/pathology , Vascular Endothelial Growth Factor A/metabolismABSTRACT
P2X(3) is a novel ATP-gated cation channel that is selectively expressed by small-diameter sensory neurones in rodents, and may play a role in nociception by binding ATP released from damaged or inflamed tissues. We have studied, for the first time, P2X(3) immunoreactivity in human inflammatory bowel disease, using Western blotting and immunohistochemistry. A major 66-kDa specific protein was found by Western blotting in all colon extracts. In the inflamed group there was a significant two-fold increase in the relative optical density of the 66-kDa band (21.2 +/- 3.1; n=8) compared to controls (11.4 +/- 3.7; n=8; P=0.009). In the control colon, P2X(3)-immunoreactive neurones were scattered throughout the myenteric and submucosal plexuses, with some neurones showing immunopositive axons/dendrites. The pattern of immunostaining was similar to the neuronal marker peripherin. In general, the intensity of the staining was greater in myenteric than submucosal neurones. The number of P2X(3)-immunoreactive neurones was significantly increased in the myenteric plexus of inflamed colon compared to controls (n=13; P=0.01). In humans, unlike rodents, P2X(3) is thus not restricted to sensory neurones. Increased P2X(3) in inflamed intestine suggests a potential role in dysmotility and pain, for which it represents a new therapeutic target.
Subject(s)
Adenosine Triphosphate/physiology , Colitis, Ulcerative/metabolism , Crohn Disease/metabolism , Ion Channel Gating , Ion Channels/metabolism , Receptors, Purinergic P2/metabolism , Blotting, Western , Colon/metabolism , Humans , Immunohistochemistry , Receptors, Purinergic P2X3 , Reference ValuesABSTRACT
OBJECTIVES: Acid-sensing ion channels (ASICs) are expressed by rat sensory neurons and may mediate pain associated with tissue acidosis after inflammation or injury. Our aim was to examine the molecular forms and localization of ASICs in human intestine and dorsal root ganglia using immunochemical techniques, and to measure the effects of inflammation and injury. DESIGN AND METHODS: Inflamed Crohn's disease intestine and injured human dorsal root ganglia, with appropriate controls, were studied by Western blotting and immunohistochemistry, using specific affinity-purified ASIC antibodies. RESULTS: In the Western blot, there was a significant three-fold increase in the mean relative optical density of the ASIC-3 55-kDa band (but not ASIC-1 or ASIC-2) in full-thickness inflamed intestine, as well as in separated muscle and mucosal layers. There was a corresponding trend for an increased immunoreactive density and increased number of ASIC-3-positive neurons in the myenteric and sub-mucous plexus of inflamed intestine. In dorsal root ganglia, immunoreactivity for all ASICs was restricted to a sub-population (about 50%) of small-diameter (nociceptor) sensory neurons, and was generally less intense after injury. CONCLUSIONS: Increased ASIC-3 in inflamed intestine suggests a role in pain or dysmotility, for which ASICs represent new therapeutic targets.
Subject(s)
Crohn Disease/metabolism , Ganglia, Spinal/chemistry , Intestines/chemistry , Membrane Proteins , Nerve Tissue Proteins , Sodium Channels/analysis , Acid Sensing Ion Channels , Adolescent , Adult , Aged , Blotting, Western , Crohn Disease/pathology , Female , Ganglia, Spinal/injuries , Humans , Immunohistochemistry , Inflammation , Intestines/innervation , Intestines/pathology , Male , Middle Aged , Myenteric Plexus/chemistry , Submucous Plexus/chemistryABSTRACT
OBJECTIVES: To determine the presence, distribution and molecular forms of the vanilloid receptor VR1, and confirm the presence and distribution of the ATP-gated ion channel P2X3 in the human urinary bladder. Materials and methods Normal urinary bladder tissues were obtained at postmortem from four subjects. Eight urinary bladder biopsies were also taken from patients with detrusor hyper-reflexia treated with intravesical resiniferatoxin. The specimens were studied using affinity-purified specific antibodies to VR1 and P2X3 by Western blotting and immunocytochemistry, and compared with immunostaining using antibodies to the pan-neuronal marker PGP 9.5 and Schwann cell marker S-100. RESULTS: VR1- and P2X3-immunoreactive fine nerve fibres were scattered throughout the suburothelium of the normal bladder and cystoscopic biopsies, and traversed the muscle layer. They had a similar distribution to PGP 9.5-immunoreactive fibres, but there were fewer, suggesting localization in subsets of axons. Western blot studies showed an expected 100-kDa VR1 protein and a P2X3-immunoreactive 66-kDa protein. Conclusion VR1 and P2X3 are present in the human urinary bladder and may contribute to distinct pathophysiological states of bladder overactivity, in accord with their differential expression in sensory neurones. Intravesical vanilloids act via VR1 and are effective in the treatment of detrusor hyper-reflexia. P2X3 may represent a selective therapeutic target for other causes of overactive bladder.
Subject(s)
Ion Channel Gating , Receptors, Drug/analysis , Receptors, Purinergic P2/analysis , Urinary Bladder/chemistry , Adenosine Triphosphate/metabolism , Aged , Blotting, Western , Female , Humans , Immunohistochemistry , Male , Middle Aged , Receptors, Drug/chemistry , Receptors, Purinergic P2/chemistry , Zebrafish ProteinsABSTRACT
Vanilloid receptor 1 (VR1) is expressed by sensory neurons. Once activated, these neurons evoke the sensation of burning pain and release neuropeptides that induce neurogenic inflammation. We used immunoblotting and immunostaining to estimate the density of VR1 in colonic tissues of patients with inflammatory bowel disease and of controls. Our study results indicate that VR1 immunoreactivity is greatly increased in colonic nerve fibres of patients with active inflammatory bowel disease. Thus, the discovery of new drugs that can bind the VR1 receptor, or antagonise endogenous inflammatory substances that activate this receptor, could lead to new therapies for pain and dysmotility.
Subject(s)
Inflammatory Bowel Diseases/metabolism , Receptors, Drug/metabolism , Humans , Immunologic Techniques , TRPV Cation ChannelsABSTRACT
The ATP-gated cation channel P2X3 is expressed selectively by rat sensory neurones, and may play a role in nociception by binding ATP released from damaged or inflamed tissues. However, the distribution of this channel in human sensory neurons is not known. Using a specific antibody, we have demonstrated intense P2X3 immunoreactivity within a subset (60%) of small/medium diameter sensory neurones and fine nerve fibres in intact post-mortem human dorsal root ganglia (DRG). Co-localization studies showed < 15% overlap with the trkA immunostaining in DRG, indicating that P2X3 was expressed predominantly in sensory neurons that are also isolectin B4 positive. There was a significant decrease in numbers of P2X3-like immunoreactive neurons in human DRG after central axotomy (to 36%), similar to the decrease in rat DRG after peripheral axotomy. However, Western blotting demonstrated a specific 66 kDa band in human DRG and peripheral organs, including intestine, where histochemistry showed P2X3 immunoreactivity in myenteric plexus neurons. Thus P2X3 antagonists may be analgesic, but are unlikely to have a selective effect on pain in humans.
Subject(s)
Ganglia, Spinal/injuries , Ganglia, Spinal/physiopathology , Nerve Degeneration/pathology , Nerve Degeneration/physiopathology , Neurons, Afferent/pathology , Receptors, Purinergic P2/metabolism , Adult , Antibody Specificity , Blotting, Western , Enteric Nervous System/metabolism , Ganglia, Autonomic/metabolism , Ganglia, Spinal/pathology , Humans , Immunohistochemistry , Receptors, Purinergic P2X3ABSTRACT
Two tetrodotoxin-resistant voltage-gated sodium channels, SNS/PN3 and SNS2/NaN, have been described recently in small-diameter sensory neurones of the rat, and play a key role in neuropathic pain. Using region-specific antibodies raised against different peptide sequences of their alpha subunits, we show by Western blot evidence for the presence of these channels in human nerves and sensory ganglia. The expected fully mature 260 kDa component of SNS/PN3 was noted in all injured nerve tissues obtained from adults; however, for SNS2/NaN, smaller bands were found, most likely arising from protein degradation. There was increased intensity of the SNS/PN3 260 kDa band in nerves proximal to the site of injury, whereas it was decreased distally, suggesting accumulation at sites of injury; all adult patients had a positive Tinel's sign at the site of nerve injury, indicating mechanical hypersensitivity. Injured nerves from human neonates showed similar results for both channels, but neonate neuromas lacked the SNS2/NaN 180 kDa molecular form, which was strongly present in adult neuromas. The distribution of SNS/PN3 and SNS2/NaN sodium channels in injured human nerves indicates that they represent targets for novel analgesics, and could account for some differences in the development of neuropathic pain in infants.
Subject(s)
Brachial Plexus/metabolism , Ganglia, Spinal/metabolism , Neuropeptides/analysis , Sodium Channels/analysis , Spinal Cord Injuries/metabolism , Adolescent , Adult , Aged , Antibodies/immunology , Blotting, Western , Brachial Plexus/injuries , Humans , Infant , Middle Aged , NAV1.8 Voltage-Gated Sodium Channel , NAV1.9 Voltage-Gated Sodium Channel , Neuropeptides/immunology , Sodium Channels/immunologyABSTRACT
Random peptide libraries (RPLs) screening with IDDM sera has identified 5 disease-specific 'mimotopes' displayed on phage (phagotopes). We characterised one phagotope (CH1p), by raising a rabbit antibody against the peptide insert on phage, which was employed in immunohistochemistry, Western blotting and cDNA libraries screening. The CH1p mimotope was detected in somatostatin cells of human islets and experimentally raised anti-osteopontin antibodies or human sera positive for the phagotope, detected a similar subpopulation of islet cells. The screening of cDNA library identified a clone corresponding to human osteopontin. In summary, RPLs proved to be successful in the identification of a novel islet-related autoantigen (osteopontin), whose significance in disease remains to be established.
Subject(s)
Autoantigens/immunology , Diabetes Mellitus, Type 1/immunology , Islets of Langerhans/immunology , Peptide Library , Sialoglycoproteins/immunology , Somatostatin/analysis , Animals , Blotting, Western , Diabetes Mellitus, Type 1/blood , Enzyme-Linked Immunosorbent Assay , Humans , Immunohistochemistry , Mass Screening/methods , Osteopontin , Rabbits , Radioimmunoassay , Recombinant Proteins/immunologyABSTRACT
The mechanisms involved in susceptibility or resistance of neoplasic cells to lysis by NK cells are not well known. We have recently described a 12-kDa factor (NK-RIF), produced and released by different tumor cell lines, making K562 resistant to NK lysis without affecting the cytotoxic function of NK effector cells. In this paper we further study the mechanism involved in NK resistance of K562 mediated by NK-RIF and its biological implications. The results show that NK-RIF does not affect the binding capacity of target and effector cells nor the levels of HLA class I antigen expression on the target cells, as a proof that resistance to NK-mediated lysis is not always associated with a defect in target effector binding or with an increased MHC class I antigen expression. However NK-RIF-treated K562 loses its capacity to induce NK cell activation and the subsequent capacity to release NKCF and makes K562 resistant to lysis by NKCF. Therefore our results show that induction of resistance to NK cytotoxicity can be the result of the modulation of target structures responsible for inducing effector cell activation without affecting target/effector binding molecules. This indicates that the structures involved in adherence and activation of NK cells have a different nature and that molecules other than HLA participate in NK resistance.
Subject(s)
Biological Factors/physiology , Cytotoxicity, Immunologic , Killer Cells, Natural/immunology , Suppressor Factors, Immunologic/physiology , Cell Line , Cytokines , Histocompatibility Antigens Class I/immunology , Humans , Immunity, Cellular , In Vitro Techniques , Receptors, Interleukin-2/physiologyABSTRACT
During an oral glucose tolerance test (oGTT) and an isoglycaemic intravenous glucose infusion, blood glucose and the responses of insulin and glucose-dependent insulinotropic polypeptide (GIP) were measured in six healthy volunteers. On a subsequent occasion a constant infusion of human synthetic GIP (2 pmol kg-1 min-1 for 30 min and 0.5 pmol kg-1 min-1 for another 30 min was given to each subject, again with a simultaneous infusion of glucose to maintain isoglycaemia to the oGTT. During the oGTT, plasma GIP concentrations rose from 92 +/- 18 pmol 1(-1) to 257 +/- 42 pmol 1(-1) 60 min after ingestion of glucose (mean +/- SEM). When glucose was administered intravenously plasma GIP levels did not rise significantly over basal. The infusion of hGIP mimicked the physiological plasma GIP response after oral glucose during the first 60 min of the study. Plasma insulin concentrations were significantly lower between 45 and 60 min than during the oGTT (438 +/- 67 vs. 200 +/- 48 pmol 1(-1); P less than 0.02; 465 +/- 96 vs. 207 +/- 48 pmol 1(-1); P less than 0.01). However, the total and incremental integrated insulin responses during the first 60 min of the study were, though lower, not significantly different from the oGTT experiment when glucose and hGIP were infused simultaneously. Thus, in the presence of mild physiological hyperglycaemia, human GIP is able to enhance the initial insulin response almost equivalently to the stimulus provided by oral glucose. Decreased insulin concentrations during porcine GIP infusions in previous experiments might be due to sequence differences between human and porcine GIP.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Gastric Inhibitory Polypeptide/pharmacology , Insulin/metabolism , Adult , Blood Glucose/metabolism , Gastric Inhibitory Polypeptide/blood , Glucose/administration & dosage , Glucose Tolerance Test , Humans , Hyperglycemia/blood , Hyperglycemia/physiopathology , Insulin/blood , Insulin Secretion , MaleABSTRACT
We have studied the effects of prepro-vasoactive intestinal polypeptide-derived peptides on lectin-induced lymphocyte proliferation and natural killer cell (NK) activity in cells from murine spleen, mesenteric lymph nodes, Peyer's patches, thymus and peripheral blood mononuclear lymphocytes (PBL). These peptides (vasoactive intestinal peptide (VIP), peptide histidine methionine (PHM-27) and peptide histidine valine (PHV-42)) showed differential effects in their immune response in a dose- and tissue-dependent manner. All peptides significantly decreased DNA synthesis in spleen (range: 45-30%), lymph nodes (range: 30-0%), Peyer's patches (range: 30-4%) and PBL (range: 30-16%). In these tissues there was no significant difference in their potency. In the thymus, however, PHM-27 (range: 27-15%) was significantly more potent (p less than 0.001) in inhibiting DNA synthesis than either VIP (range: 6-0%) or PHV-42 (range: 20-8%). The modulatory effects on NK activity by these peptides also showed an inhibitory effect. The order of potency was: VIP (range: 40-27%), PHV-42 (range: 22-11%) and PHM-27 (range: 20-8%). The presence of VIP inhibitor [( D-p-chloro-Phe6,Leu17]-VIP) at 10(-8) M in both functional assays caused a significant antagonism of the effects of VIP but not PHM-27 or PHV-42. Our results suggest the existence on lymphocytes of different receptors for prepro-VIP-derived peptides, and that they may be considered as important immunoregulatory molecules. Their mechanism of interaction, however, is not clearly understood.
Subject(s)
Killer Cells, Natural/immunology , Lymphocyte Activation/drug effects , Protein Precursors/pharmacology , Vasoactive Intestinal Peptide/pharmacology , Animals , Cytotoxicity, Immunologic/drug effects , Mice , Mice, Inbred C57BL , Receptors, Gastrointestinal Hormone/drug effects , Receptors, Vasoactive Intestinal Peptide , Vasoactive Intestinal Peptide/antagonists & inhibitorsABSTRACT
Peptide histidine valine (PHV) is a 42 amino acid polypeptide closely related to the neuropeptides VIP, PHI and PHM. We have performed a placebo-controlled, double-blind study to assess the hypothesis that the cardiovascular response to PHV infusion may be mediated via the sympathetic nervous system. Four subjects received atenolol or matched placebo 90 min prior to a controlled incremental infusion of PHV, with monitoring of heart rate, blood pressure and skin temperature. Following placebo all subjects showed a dose-related increase in heart rate and skin temperature with no effect on blood pressure during PHV infusion. beta-Blockade had no effect on skin temperature response. Pre-treatment with atenolol reduced the resting blood pressure and the maximum heart rate achieved, but did not affect the percentage increase in heart rate during PHV infusion. This suggests that the action of PHV does not involve beta-receptors. The lack of effect of PHV infusion on blood pressure, despite tachycardia and marked cutaneous vasodilatation, implies that PHV has a different effect on the resistance vessels from that of other peptides such as VIP.